Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody Summary
Ala20-Glu764
Accession # AAC16450
Applications
Human VEGFR2/KDR Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Human VEGFR2/KDR/Flk-1 by ELISA Humoral response in pre-clinical models. Specific IgG antibodies were detected by ELISA using GST-hVEGF as coating antigen (a, b, d and f). The ability of animal sera antibodies to block VEGF/VEGFR2 interaction was determined using a competitive ELISA, where a soluble VEGFR2 competes with diluted serum in plates coated with GST-hVEGF (c, e and g). CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (eight vaccinations) or bi-weekly (four vaccinations) respectively. Horizontal bars represent the mean values of antibody titer or blocking activity, which are shown for each group. p-Values were calculated according to unpaired t-test. Reference dose (A + V): 400 μg of antigen + 200 μg of VSSP; (¼Ag + ½ V): 100 μg of antigen + 100 μg of VSSP; (¼Ag + V): 100 μg of antigen + 200 μg of VSSP; (Ag + Al): 400 μg of antigen + aluminum phosphate Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28747172), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human VEGFR2/KDR/Flk-1 by ELISA Humoral response in pre-clinical models. Specific IgG antibodies were detected by ELISA using GST-hVEGF as coating antigen (a, b, d and f). The ability of animal sera antibodies to block VEGF/VEGFR2 interaction was determined using a competitive ELISA, where a soluble VEGFR2 competes with diluted serum in plates coated with GST-hVEGF (c, e and g). CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (eight vaccinations) or bi-weekly (four vaccinations) respectively. Horizontal bars represent the mean values of antibody titer or blocking activity, which are shown for each group. p-Values were calculated according to unpaired t-test. Reference dose (A + V): 400 μg of antigen + 200 μg of VSSP; (¼Ag + ½ V): 100 μg of antigen + 100 μg of VSSP; (¼Ag + V): 100 μg of antigen + 200 μg of VSSP; (Ag + Al): 400 μg of antigen + aluminum phosphate Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28747172), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human VEGFR2/KDR/Flk-1 by ELISA Humoral response in pre-clinical models. Specific IgG antibodies were detected by ELISA using GST-hVEGF as coating antigen (a, b, d and f). The ability of animal sera antibodies to block VEGF/VEGFR2 interaction was determined using a competitive ELISA, where a soluble VEGFR2 competes with diluted serum in plates coated with GST-hVEGF (c, e and g). CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (eight vaccinations) or bi-weekly (four vaccinations) respectively. Horizontal bars represent the mean values of antibody titer or blocking activity, which are shown for each group. p-Values were calculated according to unpaired t-test. Reference dose (A + V): 400 μg of antigen + 200 μg of VSSP; (¼Ag + ½ V): 100 μg of antigen + 100 μg of VSSP; (¼Ag + V): 100 μg of antigen + 200 μg of VSSP; (Ag + Al): 400 μg of antigen + aluminum phosphate Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28747172), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: VEGFR2/KDR/Flk-1
VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.
VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity.
Product Datasheets
Citations for Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
7
Citations: Showing 1 - 7
Filter your results:
Filter by:
-
A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo
Authors: Luca Rastelli, Maria Luisa Valentino, Melissa Corso Minderman, Judith Landin, Uriel M Malyankar, Mary K Lescoe et al.
International Journal of Oncology
-
Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants
Authors: J Sánchez Ra, Y Morera Día, M Bequet-Rom, F Hernández-, KH Selman-Hou, A de la Torr, ER Santiesteb, Y Martín Bau, CH Bermúdez B, J de la Torr, JV Gavilondo, M Ayala Avil
BMC Immunol., 2017-07-26;18(1):39.
Species: Human
Sample Types: Serum
Applications: ELISA Development (Detection) -
Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine
Authors: Y Morera, J Sánchez, M Bequet-Rom, KH Selman-Hou, A de la Torr, F Hernández-, Y Martín, A Garabito, J Piñero, C Bermúdez, J de la Torr, M Ayala, JV Gavilondo
Vaccine, 2017-05-20;0(0):.
Applications: ELISA Development (Detection) -
Vascular endothelial growth factor signals through platelet-derived growth factor receptor beta in meningiomas in vitro.
Br. J. Cancer, 2012-10-09;107(10):1702-13.
Species: Human
Sample Types: Cell Lysates
Applications: TaqMan Protein Assay -
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.
Authors: Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM
Br. J. Cancer, 2006-02-27;94(4):524-31.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
PEDF derived from glial Muller cells: a possible regulator of retinal angiogenesis.
Authors: Eichler W, Yafai Y, Keller T, Wiedemann P, Reichenbach A
Exp. Cell Res., 2004-09-10;299(1):68-78.
Species: Human
Sample Types: Cell Lysates, Whole Cells
Applications: Flow Cytometry, Western Blot -
The SWELL1-LRRC8 complex regulates endothelial AKT-eNOS signaling and vascular function
Authors: Ahmad F Alghanem, Javier Abello, Joshua M Maurer, Ashutosh Kumar, Chau My Ta, Susheel K Gunasekar et al.
eLife
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody and earn rewards!
Have you used Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
